Drug trial aims to tame scarring lung disease
NCT ID NCT05314517
Summary
This study tested whether a drug called namilumab could help control chronic pulmonary sarcoidosis, a disease that causes inflammation and scarring in the lungs. About 107 adults with this condition received either the drug or a placebo via injection every four weeks for six months. The main goal was to see if the drug could prevent disease flare-ups and reduce the need for strong steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kinevant Study Site
Birmingham, Alabama, 35233, United States
-
Kinevant Study Site
Palo Alto, California, 94304, United States
-
Kinevant Study Site
Valencia, California, 91355, United States
-
Kinevant Study Site
Denver, Colorado, 80206, United States
-
Kinevant Study Site
Gainesville, Florida, 32610, United States
-
Kinevant Study Site
Augusta, Georgia, 29841, United States
-
Kinevant Study Site
Chicago, Illinois, 60612, United States
-
Kinevant Study Site
Iowa City, Iowa, 52242, United States
-
Kinevant Study Site
Kansas City, Kansas, 66160, United States
-
Kinevant Study Site
New Orleans, Louisiana, 70115, United States
-
Kinevant Study Site
Baltimore, Maryland, 21234, United States
-
Kinevant Study Site
Minneapolis, Minnesota, 55414, United States
-
Kinevant Study Site
Rochester, Minnesota, 55905, United States
-
Kinevant Study Site
Greenville, North Carolina, 27834, United States
-
Kinevant Study Site
Cincinnati, Ohio, 45219, United States
-
Kinevant Study Site
Cleveland, Ohio, 44195, United States
-
Kinevant Study Site
Philadelphia, Pennsylvania, 19140, United States
-
Kinevant Study Site
Pittsburgh, Pennsylvania, 15213, United States
-
Kinevant Study Site
Charleston, South Carolina, 29425, United States
-
Kinevant Study Site
Rock Hill, South Carolina, 29732, United States
-
Kinevant Study Site
Dallas, Texas, 75390, United States
-
Kinevant Study Site
Houston, Texas, 77030, United States
-
Kinevant Study Site
Charlottesville, Virginia, 22908, United States
-
Kinevant Study Site
Falls Church, Virginia, 22042, United States
-
Kinevant Study Site
Brussels, 1200, Belgium
-
Kinevant Study Site
Leuven, 3000, Belgium
-
Kinevant Study Site
Liège, B-4000, Belgium
-
Kinevant Study Site
Yvoir, 5530, Belgium
-
Kinevant Study Site
Bobigny, 93000, France
-
Kinevant Study Site
Lille, 59037, France
-
Kinevant Study Site
Paris, 75018, France
-
Kinevant Study Site
Berlin, 14165, Germany
-
Kinevant Study Site
Essen, 45239, Germany
-
Kinevant Study Site
Freiburg im Breisgau, 79106, Germany
-
Kinevant Study Site
Hanover, 30625, Germany
-
Kinevant Study Site
Heidelberg, 69126, Germany
-
Kinevant Study Site
Leiden, 2333 ZA, Netherlands
-
Kinevant Study Site
Nieuwegein, 3435 CM, Netherlands
-
Kinevant Study Site
Rotterdam, 3015 GD, Netherlands
-
Kinevant Study Site
Ankara, 06620, Turkey (Türkiye)
-
Kinevant Study Site
Istanbul, 34134, Turkey (Türkiye)
-
Kinevant Study Site
Izmir, 35100, Turkey (Türkiye)
-
Kinevant Study Site
Izmir, 35330, Turkey (Türkiye)
-
Kinevant Study Site
Mersin, 33110, Turkey (Türkiye)
-
Kinevant Study Site
Cambridge, CB20QQ, United Kingdom
-
Kinevant Study Site
Cottingham, HU165JQ, United Kingdom
-
Kinevant Study Site
London, SE59RS, United Kingdom
Conditions
Explore the condition pages connected to this study.